上海微创心脉医疗科技(集团)股份有限公司2025年第二次临时股东会决议公告

Group 1 - The company held its second extraordinary general meeting of shareholders on December 31, 2025, with no resolutions being rejected [2][5] - The meeting was conducted in compliance with the Company Law, Securities Law, and the company's articles of association, utilizing both on-site and online voting methods [2][4] - All resolutions discussed at the meeting were ordinary resolutions, approved by more than half of the voting rights held by attending shareholders or their proxies [4] Group 2 - The meeting was attended by all eight current directors and the company secretary, along with some senior executives and a witnessing lawyer [3] - The witnessing law firm, Beijing Jiayuan Law Firm, confirmed that the meeting's procedures and voting were in accordance with legal regulations and the company's articles of association, deeming the voting results valid [6]

Endovastec-上海微创心脉医疗科技(集团)股份有限公司2025年第二次临时股东会决议公告 - Reportify